MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Fry, D. W.
Right arrow Articles by Besserer, J. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fry, D. W.
Right arrow Articles by Besserer, J. A.

Biochemical pharmacology and DNA-drug interactions by Cl-958, a new antitumor intercalator derived from a series of substituted 2H- [1]benzothiopyrano[4,3,2-cd]indazoles

DW Fry and JA Besserer

Warner-Lambert/Parke-Davis Pharmaceutical Research, Ann Arbor, Michigan 48105.

Cl-958, PD 121373, and PD 114595 belong to a new class of DNA complexers, substituted 2H-[1]benzothiopyrano[4,3,2-cd] indazoles, and are being further developed as antitumor drugs based on their curative properties against murine solid tumor models. The biochemical effects of these drugs on L1210 leukemia cells and their interaction with DNA were studied and compared to clinically used intercalators. The benzothiopyranoindazoles bound to DNA with a relatively high affinity, having intrinsic association constants of between 3 and 4 x 10(5) M-1. Based on viscosity measurements, the mode of DNA binding appears to be through intercalation. Unwinding angles were calculated to be approximately 18 degrees. The benzothiopyranoindazoles were potent inhibitors of nucleic acid synthesis, reducing both DNA and RNA synthesis to the same extent at similar concentrations. Like other known intercalators, these compounds produced DNA single- and double- strand breaks in a time- and concentration-dependent manner in L1210 cells. Between one and two DNA strand breaks were formed per protein- strand crosslink. Repair of these DNA lesions after the drug was removed from the cells was either very slow or did not occur at all for at least 2 hr. Finally, since the high incidence of cardiotoxicity associated with the administration of anthracyclines has been related to the formation of reactive oxygen species, the ability of the benzothiopyranoindazoles to augment superoxide dismutase-sensitive oxygen consumption was observed in a rat liver microsomal system. These compounds produced less than 5% of the activity in this assay that doxorubicin produced.

Volume 33, Issue 1, pp. 84-92, 01/01/1988
Copyright © 1988 by American Society for Pharmacology and Experimental Therapeutics




This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
E. C. Dees, L. R. Whitfield, W. R. Grove, S. Rummel, L. B. Grochow, and R. C. Donehower
A Phase I and Pharmacologic Evaluation of the DNA Intercalator CI-958 in Patients with Advanced Solid Tumors
Clin. Cancer Res., October 1, 2000; 6(10): 3885 - 3894.
[Abstract] [Full Text]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1988 by the American Society for Pharmacology and Experimental Therapeutics